MDD
58 programs · 58 companies
Programs
58
Companies
58
Trials
50
MOAs
36
KIF18AiBCMA ADCPI3KiHPK1iCGRPantSHP2iCD47iPARPiUSP1iSOS1i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Pexatenlimab | Phase 1/2 | GPRC5D | ||
| GIL-9779 | Phase 1 | IL-17A | ||
| REG-3155 | Phase 1/2 | MDM2 | ||
| Bemanesiran | Phase 3 | PLK4 | ||
| Sematapinarof | NDA/BLA | VEGF | ||
| Nirafotisoran | Phase 2/3 | TROP-2 | ||
| Fixalucimab | Phase 1/2 | IL-23 | ||
| Kemanesiran | Approved | JAK1 | ||
| VYG-2926 | NDA/BLA | CD19 | ||
| Gozelucimab | Phase 1/2 | Nectin-4 | ||
| Ribonesiran | Phase 1/2 | IL-23 | ||
| Gelibrutinib | NDA/BLA | EZH2 | ||
| NIA-IIT-413 | Phase 2 | MET | ||
| Miriinavolisib | Phase 3 | Nectin-4 | ||
| Niraratamab | Phase 2 | B7-H3 | ||
| MOR-3625 | NDA/BLA | GIP-R | ||
| SCO-5362 | NDA/BLA | USP1 | ||
| Zoriosocimab | Approved | AHR | ||
| Ribomavacamten | Phase 3 | BTK | ||
| Surafotisoran | Phase 2 | APOC3 | ||
| Daranesiran | Phase 2/3 | CGRP | ||
| Teralucimab | Approved | SMN2 | ||
| ANR-8751 | Phase 2/3 | CDK2 | ||
| Capibrutinib | Approved | TROP-2 | ||
| ACC-8527 | Approved | KRASG12D | ||
| ALE-8045 | Phase 1 | FXIa | ||
| Liraratamab | Approved | FcRn | ||
| Rimanesiran | Phase 3 | BET | ||
| Mirilemzoparlimab | Phase 2 | CD20 | ||
| Doxarasimod | Phase 3 | GLP-1R | ||
| Polainavolisib | Phase 2/3 | FcRn | ||
| Nirarapivir | Approved | GIP-R | ||
| BBI-8786 | Phase 2 | EZH2 | ||
| PLR-1516 | Phase 1 | Cl18.2 | ||
| TUR-4491 | NDA/BLA | C5 | ||
| PMV-7390 | Phase 2 | KIF18A | ||
| Tixatuximab | Phase 3 | PRMT5 | ||
| 418-7316 | Phase 2/3 | KRASG12C | ||
| NIC-5654 | Phase 1/2 | SOS1 | ||
| 069-1659 | Preclinical | C5 | ||
| Riboinavolisib | Phase 2 | CD38 | ||
| Bemazanubrutinib | Approved | AuroraA | ||
| Nidaosocimab | Phase 1 | PCSK9 | ||
| IMM-6534 | Phase 1/2 | Nectin-4 | ||
| Elracapivasertib | Approved | PD-L1 | ||
| AVR-5957 | NDA/BLA | EZH2 | ||
| Zanurelsin | NDA/BLA | SMN2 | ||
| Gelilemzoparlimab | Approved | KRASG12D | ||
| Bematinib | Phase 2 | KRASG12C | ||
| ZYD-981 | Preclinical | TIGIT | ||
| VIN-2751 | Phase 2/3 | PARP | ||
| Polalemzoparlimab | Approved | GPRC5D | ||
| Niraratamab | Phase 2/3 | RET | ||
| Darasertib | Phase 1 | Nectin-4 | ||
| DEC-1380 | Preclinical | PD-L1 | ||
| SYN-451 | NDA/BLA | SGLT2 | ||
| DYN-8432 | Phase 1/2 | USP1 | ||
| VEE-7651 | Preclinical | CDK4/6 |
Trials (50)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT04084793 | Pexatenlimab | Phase 1/2 | Recruiting |
| NCT03080412 | GIL-9779 | Phase 1 | Active |
| NCT03162673 | Bemanesiran | Phase 3 | Terminated |
| NCT04418595 | Bemanesiran | Phase 3 | Not yet recr... |
| NCT04410694 | Bemanesiran | Phase 3 | Active |
| NCT03117480 | Nirafotisoran | Phase 2/3 | Active |
| NCT04422799 | Fixalucimab | Phase 1/2 | Completed |
| NCT07169758 | Fixalucimab | Phase 1/2 | Active |
| NCT07190687 | Kemanesiran | Approved | Terminated |
| NCT03271951 | Kemanesiran | Approved | Recruiting |
| NCT05864203 | Gozelucimab | Phase 1/2 | Active |
| NCT05421631 | Gozelucimab | Phase 1/2 | Recruiting |
| NCT04600093 | Ribonesiran | Phase 1/2 | Recruiting |
| NCT03370757 | NIA-IIT-413 | Phase 2 | Terminated |
| NCT04735132 | Niraratamab | Phase 2 | Terminated |
| NCT05927516 | SCO-5362 | NDA/BLA | Not yet recr... |
| NCT06048523 | Zoriosocimab | Approved | Active |
| NCT08946581 | Ribomavacamten | Phase 3 | Recruiting |
| NCT03272473 | Surafotisoran | Phase 2 | Terminated |
| NCT06147408 | ANR-8751 | Phase 2/3 | Completed |